These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36309347)

  • 1. The Incidence and Effect of Adverse Events Due to COVID-19 Vaccines on Breakthrough Infections: Decentralized Observational Study With Underrepresented Groups.
    Gabashvili IS
    JMIR Form Res; 2022 Nov; 6(11):e41914. PubMed ID: 36309347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccination Reactions and Risk of Breakthrough Infections Among People With Diabetes: Cohort Study Derived From Community Reporters.
    Dreyer NA; Knuth KB; Xie Y; Reynolds MW; Mack CD
    JMIR Diabetes; 2024 Feb; 9():e45536. PubMed ID: 38412008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of a Brief, Altruism-Eliciting Video Intervention in Enhancing COVID-19 Vaccination Intentions Among a Population-Based Sample of Younger Adults: Randomized Controlled Trial.
    Zhu P; Tatar O; Griffin-Mathieu G; Perez S; Haward B; Zimet G; Tunis M; Dubé È; Rosberger Z
    JMIR Public Health Surveill; 2022 May; 8(5):e37328. PubMed ID: 35544437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
    Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
    Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization coverage levels among 19- to 35-month-old children in 4 diverse, medically underserved areas of the United States.
    Rosenthal J; Rodewald L; McCauley M; Berman S; Irigoyen M; Sawyer M; Yusuf H; Davis R; Kalton G
    Pediatrics; 2004 Apr; 113(4):e296-302. PubMed ID: 15060256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers.
    Tosun S; Ozkan Ozdemir H; Erdogan E; Akcay S; Aysin M; Eskut N; Ortan P; Eskut B
    Postgrad Med; 2022 Jan; 134(1):104-110. PubMed ID: 34705583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving pediatric COVID-19 vaccine uptake using an mHealth tool (MoVeUP): a randomized, controlled trial.
    McCulloh RJ; Darden P; Snowden J; Ounpraseuth S; Lee J; Clarke M; Newcomer SR; Fu L; Hubberd D; Baldner J; Garza M; Kerns E
    Res Sq; 2022 Oct; ():. PubMed ID: 36238712
    [No Abstract]   [Full Text] [Related]  

  • 16. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
    Arora G; Taneja J; Bhardwaj P; Goyal S; Naidu K; Yadav SK; Saluja D; Jetly S
    J Med Virol; 2022 Jul; 94(7):3147-3154. PubMed ID: 35261064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ontology of Vaccine Adverse Events (OVAE) and its usage in representing and analyzing adverse events associated with US-licensed human vaccines.
    Marcos E; Zhao B; He Y
    J Biomed Semantics; 2013 Nov; 4(1):40. PubMed ID: 24279920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study.
    Bouwmans P; Messchendorp AL; Sanders JS; Hilbrands L; Reinders MEJ; Vart P; Bemelman FJ; Abrahams AC; van den Dorpel MA; Ten Dam MA; de Vries APJ; Rispens T; Steenhuis M; Gansevoort RT; Hemmelder MH;
    BMC Nephrol; 2022 Feb; 23(1):55. PubMed ID: 35123437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.